Uncertainties cloud Pharmaniaga


The optimism on the new vaccine division, which hinges solely on the Sinovac vaccine, looks uncertain and makes earnings forecasts difficult.

PETALING JAYA: Earnings visibility appears murky beyond 2021 for Pharmaniaga Bhd as it has yet to get an extension for its medical supply contract from the government which expires by year-end.

Pharmaniaga is the largest listed pharmaceutical company in the country by revenue with the government’s drug and medical supply concession in-hand.

Start your ads-free experience now!

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

Shanghai shares end at two-month low as traders gauge lacklustre data
Gold subdued as investors await further data for Fed rate cues
BOJ to forgo July rate hike, taper US$152bil per year, says ex-policymaker
Oil prices slip on weaker US consumer demand, rise in China output
Thai baht declines in thin holiday trading across Asian markets
Asia shares muted on China data, euro on defensive
L'Occitane chairman Geiger offers scrip alternative to take firm private
China stocks down on weaker-than-expected data, HK shares up
China new home prices fall at fastest clip in nearly 10 years
Asia shares muted on mixed China data, euro pressure

Others Also Read